Further Improvement in Postprandial Glucose Control With Addition of Exenatide or Sitagliptin to Combination Therapy With Insulin Glargine and Metformin
Diabetes Care2010Vol. 33(7), pp. 1509–1515
Citations Over TimeTop 1% of 2010 papers
Sabine Arnolds, Sibylle Dellweg, Janina Clair, Marie‐Paule Dain, Michael A. Nauck, Klaus Rave, Christoph Kapitza
Abstract
EXE or SITA added to GLAR + MET further substantially reduced postprandial blood glucose excursions. Longer-term studies in a larger population are warranted to confirm these findings.
Related Papers
- → The effect of initial therapy with the fixed‐dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus(2011)90 cited
- → Differences in baseline characteristics between patients prescribed sitagliptin versus exenatide based on a US electronic medical record database(2010)8 cited
- → Valutazione economica del trattamento con exenatide o sitagliptin di pazienti affetti da diabete tipo 2 in Italia(2011)2 cited
- → Sitagliptin or exenatide once weekly for type 2 diabetes: comparison of the clinical trials(2011)1 cited
- → In T2D patients with baseline A1c <8.0%, liraglutide achieves A1c targets more often than sitagliptin or exenatide(2013)